InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights Preclinical Data on GITR Agonist KROS 101 at AACR-JCA Conference
Kairos Pharma (NYSE American: KAPA) presented preclinical data on its GITR agonist, KROS 101, during the plenary session of the AACR-JCA conference. The study demonstrated that KROS 101 enhances T cell infiltration, proliferation, and tumor-killing ability in melanoma and glioblastoma models while reducing regulatory T-cell suppression. Compared to the GITR antibody TRX518, KROS 101 showed superior tumor reduction in a human GITR knock-in mouse model. The…